Drug Profile
ORD 2020
Latest Information Update: 15 Dec 2010
Price :
$50
*
At a glance
- Originator POZEN
- Class Antiulcers
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Gastro-oesophageal reflux
Most Recent Events
- 15 Dec 2010 No development reported - Phase-I for Gastro-oesophageal reflux in USA (PO)
- 20 Mar 2009 Phase-I clinical trials in Gastro-oesophageal reflux in USA (PO)